Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Timely controlled T cell receptor expression of genetically engineered precursor T cells requires early transgene induction for leukemia control after hematopoietic stem cell transplantation
    Meeting Abstract

    Hoseini, S. S.; Hapke, M.; Herbst, J.; Wedekind, D.; Baumann, R.; Krueger, A.; Heinz, N.; Schiedlmeier, B.; Vignali, D.; van den Brink, M. R. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Porcu, P.; Flinn, I.; Kahl, B. S.; Sweeney, J.; Stern, H. M.; Douglas, M.; Allen, K.; Kelly, P.; Foss, F. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Clinical utility of comprehensive profiling of genomic alterations in hematologic malignancies
    Meeting Abstract

    He, J.; Bufill, J. A.; Nahas, M. K.; Wang, K.; Young, L. E.; Knapp, K. M.; Brennan, K. W.; Donahue, A. L.; Young, G.; Ross, J. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Conditional loss of Dnmt3a results in myeloproliferation and liver-specific myeloid expansion
    Meeting Abstract

    Guryanova, O. A.; Lieu, Y.; Shank, K. R.; Rivera, S.; Garrett-Bakelman, F. E.; Glass, J.; Keller, M. D.; Pandey, S.; Tovbin, D.; Weinstein, A. R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: Results from the fully accrued global phase 2 CPKC412D2201 trial
    Meeting Abstract

    Gotlib, J.; Kluin-Nelemans, H. C.; George, T. I.; Akin, C.; Sotlar, K.; Hermine, O.; Awan, F.; Hexner, E. O.; Mauro, M.; Sternberg, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Meeting Abstract

    Gore, L.; Locatelli, F.; Zugmaier, G.; Zwaan, C. M.; Bhojwani, D.; Handgretinger, R.; Bader, P.; O'Brien, M. M.; Trippett, T. M.; Brethon, B.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic analysis of serial samples from CLL patients identifies clonal events associated with disease progression
    Meeting Abstract

    Gardner, J. R.; Nahas, M.; He, J.; Aumann, S.; Gonen, M.; Patel, M.; Knapp, K. M.; Palomba, M. L.; Yelensky, R.; Donahue, A. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Minimal residual disease assessment by flow cytometry in AML is an independant prognostic factor even after adjusting for cytogenetic/molecular abnormalities
    Meeting Abstract

    Ganzel, C.; Sun, Z. X.; Gonen, M.; Patel, J. P.; Abdel-Wahab, O.; Fernandez, H. F.; Rowe, J. M.; Tallman, M. S.; Levine, R. L.; Paietta, E. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Secondary ALL may be independent of prior cytotoxic therapy
    Meeting Abstract

    Ganzel, C.; Devlin, S. M.; Douer, D.; Stein, E. M.; Rowe, J. M.; Tallman, M. S.
    Blood (2014)

    Fulltext@MSK | Save